WO1996023500A1 - Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion - Google Patents

Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion Download PDF

Info

Publication number
WO1996023500A1
WO1996023500A1 PCT/ES1996/000013 ES9600013W WO9623500A1 WO 1996023500 A1 WO1996023500 A1 WO 1996023500A1 ES 9600013 W ES9600013 W ES 9600013W WO 9623500 A1 WO9623500 A1 WO 9623500A1
Authority
WO
WIPO (PCT)
Prior art keywords
inert
acid
polymer
labile
compound
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Ceased
Application number
PCT/ES1996/000013
Other languages
English (en)
Spanish (es)
French (fr)
Inventor
Montserrat Ballester Rodes
Marinus Van Boven
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Esteve Quimica SA
Original Assignee
Esteve Quimica SA
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=8289322&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=WO1996023500(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Priority to AT96901349T priority Critical patent/ATE193649T1/de
Priority to SI9630226T priority patent/SI0773025T1/xx
Priority to EP96901349A priority patent/EP0773025B1/en
Priority to KR1019960704702A priority patent/KR100331290B1/ko
Priority to JP52327896A priority patent/JP4183746B2/ja
Priority to AU45403/96A priority patent/AU4540396A/en
Priority to DK96901349T priority patent/DK0773025T3/da
Priority to CA002184842A priority patent/CA2184842C/en
Priority to HU9603014A priority patent/HU229219B1/hu
Application filed by Esteve Quimica SA filed Critical Esteve Quimica SA
Priority to DE69608767T priority patent/DE69608767D1/de
Priority to ES96901349T priority patent/ES2148725T3/es
Publication of WO1996023500A1 publication Critical patent/WO1996023500A1/es
Priority to FI963916A priority patent/FI121730B/fi
Anticipated expiration legal-status Critical
Ceased legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A61K31/4427—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems
    • A61K31/4439—Non condensed pyridines; Hydrogenated derivatives thereof containing further heterocyclic ring systems containing a five-membered ring with nitrogen as a ring hetero atom, e.g. omeprazole
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/44—Non condensed pyridines; Hydrogenated derivatives thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/50—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals
    • A61K9/5073—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings
    • A61K9/5078—Microcapsules having a gas, liquid or semi-solid filling; Solid microparticles or pellets surrounded by a distinct coating layer, e.g. coated microspheres, coated drug crystals having two or more different coatings optionally including drug-containing subcoatings with drug-free core
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
    • A61P1/04—Drugs for disorders of the alimentary tract or the digestive system for ulcers, gastritis or reflux esophagitis, e.g. antacids, inhibitors of acid secretion, mucosal protectants
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
    • A61P31/04—Antibacterial agents

Definitions

  • the present invention relates to novel pharmaceutical preparations for oral administration containing a 2 [(2-pyridyl) methylsulfinyl] -benzimidazole derivative (hereinafter referred to as "benzimidazole compound”) of formula I:
  • R- ⁇ is hydrogen, methoxy or difluoromethoxy
  • R.2 is methyl or methoxy
  • R3 is methoxy, 2,2,2-trifluoroethoxy or 3- methoxypropoxy
  • R4 is hydrogen or methyl
  • the invention is also related to a method for the manufacture of said preparations, and the ways of administration to patients with gastrointestinal diseases.
  • the referred benzimidazole compounds are very effective medications for the treatment of gastric and duodenal ulcers, gastroesophageal reflux, severe erosive esophagitis, and in the eradication of H-pylori.
  • these compounds are little stable In solid state they are sensitive to heat, humidity and light, and in aqueous solution or suspension stability decreases with decreasing pH. The degradation of these compounds is catalyzed by acid reaction compounds.
  • compositions containing acid-labile compounds should be undercoated to avoid a reaction between the active ingredient and the external acidic enteric coating. Such a reaction, if any, would cause degradation, destabilization and consequently alteration of the color of the active ingredient.
  • an alkaline salt of the benzimidazole compound or by incorporating an alkaline reaction compound in the enteric coated preparation (oxide, hydroxide or magnesium carbonate, aluminum hydroxide, carbonate, phosphate or citrate Aluminum, calcium, sodium or potassium, aluminum / magnesium composite material, sodium lauryl sulfate, amino acids, N-methyl-D-glucam; .na, etc.) as described in US-A- 4,786,505, US-A-5,232,706, EP-A-237200, EP-A-124495, the alkaline reaction compound being present within or on the surface of the core together with the benzimidazole compound.
  • solid pharmaceutical preparations of high stability are obtained containing a benzimidazole compound of Formula I.
  • the new galenic formulations do not contain alkaline reaction compounds, therefore, an alkaline compound is not present within the preparations. enterically coated.
  • the new preparations described have great stability during storage over long periods of time, far superior to that of known formulations, avoiding loss of color and richness, thus being more suitable for pharmaceutical use.
  • the new preparation is characterized by an inert spherical core of sugar and starch, on which a first coating layer containing a mixture of the benzimidazolic compound of Formula I is applied as active ingredient, an inert water soluble polymer and reaction excipients non - alkaline pharmaceutical acceptable ⁇ ; a second inert insulating layer formed by water soluble polymers and compatible excipients; and finally a third layer consisting of an enteric coating.
  • the core, the process conditions and the excipients have been selected in order to obtain an effective coating, required in each layer.
  • the new preparation obtained is resistant to dissolution in acidic medium being stable during the passage through gastric juice, and quickly dissolves in a neutral or alkaline medium, conditions of the proximal part of the small intestine.
  • the acid resistance evaluated according to Farri.acopea USA, demonstrates that after 2 hours the amount of benzimidazole remains unchanged, and that by changing the pH to 6.8, after 30 minutes all the benzimidazole dissolves (analyzed according to Pharmacopoeia USA).
  • inert spherical cores are coated with a first layer containing the benzimidazole acid-labile compound, an inert water soluble polymer such as hydroxypropyl methylcellulose or hydroxypropyl cellulose, and talc. It is then coated with a second layer consisting of a water soluble inert polymer such as hydroxypropylmethylcellulose or hydroxypropylcellulose, talc and a pigment such as titanium dioxide.
  • a third, enteric layer is applied, consisting of a polymer resistant to gastric juice such as methacrylic acid / methyl ester of copolymerized methacrylic acid, a plasticizer such as triethyl citrate or the like, and talc.
  • the layers are applied by conventional fluid bed coating techniques using aqueous solutions or dispersions.
  • the active ingredients can be administered in the same doses and according to the same protocol as the corresponding already commercial forms.
  • the final dose may be administered in the form of capsules containing the pellets or pellets formulated as tablets.
  • the dose for the benzimidazole compound is between 1 mg and 100 mg / kg / day, adjusted to the needs of each patient and for the clinically indicated time.
  • a fluid bed apparatus 3010 g of uniform spherical inert sugar and starch nuclei (composition according to Pharmacopoeia USA) are introduced, onto which the previously obtained dispersion is sprayed. After spraying, and before applying the second layer, the spheres are dried.
  • pellets thus obtained were stored in closed polyethylene bags inside a cardboard bottle as well as in closed glass jars, and were subjected to the so-called accelerated conditions, that is, 40 ⁇ C and 75% relative humidity.
  • pellets extracted from Prilosec® capsules (trademark of Merck / Astra) were packed in identical containers and subjected to the same conditions.
  • the test results in accelerated conditions are summarized in Tables 1, 2 and 3, demonstrating superior stability of the new pellets against the authorized products available in the market.
  • Second layer 350 g of deionized water, 52 g of hydroxypropyl methylcellulose, 7 g of talc and 7 g of titanium dioxide.
  • Enteric coating layer 280 g of deionized water, 290 g of methacrylic acid copolymer according to Pharmacopoeia USA - aqueous suspension type C-, 13 g of triethyl citrate and 13 g of talc.
  • the pellets obtained were stable and showed a profile similar to those obtained in example 1.
  • the purpose of the study was to investigate the bioavailability and pharmacokinetic profile of the new pharmaceutical formulation of omeprazole compared to the standard capsule formulation (Prilosec®; 20 mg).
  • Hard gelatin capsules were filled with the new galenic form of omeprazole, prepared according to example 1, in an amount equivalent to 20 mg of omeprazole.
  • the experimental design carried out in a single center, was an open, randomized, crossed study in 24 healthy volunteers, male and female.
  • the medication was administered with 200 ml of tap water after fasting (solid and liquids), at least, during the previous 10 hours.
  • the concentration of omeprazole in blood plasma was analyzed by a validated method of high pressure liquid chromatography with ultraviolet detector
  • Teeth values for the geometric mean of the maximum plasma concentration C ma ⁇ were 249 (197) and 241 (174) ng / ml, and the AUC Q - ⁇ were 434 (440) and 486 (436) ng h / ml, respectively.
  • the ratio of the geometric means (new / Prilo-sec®) of C ma ⁇ and AUC was 1.03 in both cases, and the 90% confidence intervals (CI) for these relationships were completely within the range 0 , 80 - 1.25. According to the CPMP directives for bioequivalence studies, the bioequivalence of the formulations (new formulation and Prilosec®) is accepted
  • omeprazole capsules according to the present invention, a preparation is obtained with the same bioavailability as Prilosec® capsules containing the same amount of micronized active compound.

Landscapes

  • Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Veterinary Medicine (AREA)
  • Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Medicinal Chemistry (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Organic Chemistry (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Oncology (AREA)
  • Communicable Diseases (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Medicinal Preparation (AREA)
  • Plural Heterocyclic Compounds (AREA)
PCT/ES1996/000013 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion Ceased WO1996023500A1 (es)

Priority Applications (12)

Application Number Priority Date Filing Date Title
ES96901349T ES2148725T3 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion.
DK96901349T DK0773025T3 (da) 1995-02-01 1996-01-26 Nye stabile galeniske formuleringer indeholdende en syrelabil benzimidazolforbindelser, og fremgangsmåde til fremstilling
EP96901349A EP0773025B1 (en) 1995-02-01 1996-01-26 New stable galenic formulations containing an acid-labile benzimidazol compound, and production process
KR1019960704702A KR100331290B1 (ko) 1995-02-01 1996-01-26 산에불안정한벤즈이미다졸화합물을포함하는신규의안정화된갈레닉(Galenic)제제및그의제조방법
JP52327896A JP4183746B2 (ja) 1995-02-01 1996-01-26 酸不安定性ベンズイミダゾールを含有する新規安定型ガレニック製剤、及びその製造方法
AU45403/96A AU4540396A (en) 1995-02-01 1996-01-26 New stable ganelic formulations containing an acid-labile benzimidazol compound, and production process
CA002184842A CA2184842C (en) 1995-02-01 1996-01-26 New stabilized galenic formulations comprising an acid labile benzimidazole compound and its preparation
AT96901349T ATE193649T1 (de) 1995-02-01 1996-01-26 Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren
HU9603014A HU229219B1 (en) 1995-02-01 1996-01-26 Stabilized galenic compositions containing benzimidazol derivatives decomposing in acidic medium, and process for producing them
SI9630226T SI0773025T1 (en) 1995-02-01 1996-01-26 New stable galenic formulations containing an acid-labile benzimidazol compound, and production process
DE69608767T DE69608767D1 (de) 1995-02-01 1996-01-26 Neue stabile galenische formulierungen, die eine säurelabile benzimidazolverbindung enthalten, und herstellungsverfahren
FI963916A FI121730B (fi) 1995-02-01 1996-09-30 Uudet stabiloidut galeeniset formulaatiot, jotka sisältävät happolabiilia bentsimidatsoliyhdistettä, ja niiden valmistus

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
ESP9500181 1995-02-01
ES09500181A ES2094694B1 (es) 1995-02-01 1995-02-01 Nueva formulacion farmaceuticamente estable de un compuesto de bencimidazol y su proceso de obtencion.

Publications (1)

Publication Number Publication Date
WO1996023500A1 true WO1996023500A1 (es) 1996-08-08

Family

ID=8289322

Family Applications (1)

Application Number Title Priority Date Filing Date
PCT/ES1996/000013 Ceased WO1996023500A1 (es) 1995-02-01 1996-01-26 Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion

Country Status (20)

Country Link
US (1) US5626875A (https=)
EP (2) EP0773025B1 (https=)
JP (1) JP4183746B2 (https=)
KR (1) KR100331290B1 (https=)
AR (1) AR002702A1 (https=)
AT (2) ATE193649T1 (https=)
AU (1) AU4540396A (https=)
CA (1) CA2184842C (https=)
DE (3) DE69608767D1 (https=)
DK (2) DK0773025T3 (https=)
ES (3) ES2094694B1 (https=)
FI (1) FI121730B (https=)
HU (1) HU229219B1 (https=)
IL (1) IL116673A (https=)
IN (1) IN186596B (https=)
PT (2) PT993830E (https=)
SI (2) SI0993830T1 (https=)
TW (1) TW503115B (https=)
WO (1) WO1996023500A1 (https=)
ZA (1) ZA96683B (https=)

Cited By (6)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1999053918A1 (en) 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US6391342B1 (en) 1998-03-20 2002-05-21 A/S Gea Farmaceutisk Fabrik Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl] sulfinyl benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
US6576258B1 (en) 1997-07-14 2003-06-10 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Pharmaceutical formulation with controlled release of active substances
US7402321B2 (en) 1998-08-12 2008-07-22 Nycomed Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
US7544370B2 (en) 2003-10-01 2009-06-09 Wyeth Pantoprazole multiparticulate formulations
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations

Families Citing this family (75)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
SE9500478D0 (sv) * 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process
ATE286394T1 (de) 1995-09-21 2005-01-15 Pharma Pass Ii Llc Ein säurelabile omeprazol enthaltende arzneizusammensetzung und verfahren zu deren herstellung
ES2137862B1 (es) * 1997-07-31 2000-09-16 Intexim S A Preparacion farmaceutica oral que comprende un compuesto de actividad antiulcerosa y procedimiento para su obtencion.
US6274591B1 (en) 1997-11-03 2001-08-14 Joseph F. Foss Use of methylnaltrexone and related compounds
US6559158B1 (en) 1997-11-03 2003-05-06 Ur Labs, Inc. Use of methylnaltrexone and related compounds to treat chronic opioid use side affects
US20030158220A1 (en) * 1997-11-03 2003-08-21 Foss Joseph F. Use of methylnaltrexone and related compounds to treat chronic opioid use side effects
FR2774288B1 (fr) † 1998-01-30 2001-09-07 Ethypharm Sa Microgranules d'omeprazole gastroproteges, procede d'obtention et preparations pharmaceutiques
ZA9810765B (en) * 1998-05-28 1999-08-06 Ranbaxy Lab Ltd Stable oral pharmaceutical composition containing a substituted pyridylsulfinyl benzimidazole.
FR2793688B1 (fr) * 1999-05-21 2003-06-13 Ethypharm Lab Prod Ethiques Microgranules gastroproteges, procede d'obtention et preparations pharmaceutiques
ES2168043B1 (es) * 1999-09-13 2003-04-01 Esteve Labor Dr Forma farmaceutica solida oral de liberacion modificada que contiene un compuesto de bencimidazol labil en medio acido.
AU782538B2 (en) 1999-10-20 2005-08-04 Eisai Co. Ltd. Method for stabilizing benzimidazole compounds
DE19959419A1 (de) * 1999-12-09 2001-06-21 Ratiopharm Gmbh Stabile galenische Zubereitungen umfassend ein Benzimidazol und Verfahren zu ihrer Herstellung
EP1108425B1 (en) * 1999-12-16 2005-06-08 Laboratorio Medinfar-Produtos Farmaceuticos, S.A. New stable multi-unitary pharmaceutical preparations containing substituted benzimidazoles
US6419956B1 (en) * 1999-12-30 2002-07-16 Ancile Pharmaceuticals Odor-masking coating for a pharmaceutical preparation
WO2002026210A2 (en) * 2000-09-29 2002-04-04 Geneva Pharmaceuticals Inc. Proton pump inhibitor formulation
WO2002038133A2 (en) * 2000-11-10 2002-05-16 F. Hoffman-La Roche Ag Compositions containing hydrolytically unstable compounds
US20030022909A1 (en) * 2001-06-05 2003-01-30 University Of Chicago Use of methylnaltrexone to treat immune suppression
AU2002321204B2 (en) 2001-07-16 2008-05-08 Janssen Pharmaceutica N.V. Improved process for preparing benzimidazole-type compounds
NZ532096A (en) * 2001-09-28 2006-10-27 Mcneil Ppc Inc Dosage forms having an inner core and outer shell with different shapes
US20040170689A1 (en) * 2001-11-09 2004-09-02 Odink Debra Alida Stabilized formulations comprising hydrolytically unstable compositions
ES2198195B1 (es) 2001-12-18 2004-10-01 Laboratorios Del Dr. Esteve, S.A. Forma de dosificacion farmaceutica oral comprimida, con recubrimiento enterico, que contiene un compuesto de bencimidazol labil en medio acido.
RU2332237C2 (ru) * 2002-08-02 2008-08-27 Рациофарм Гмбх Фармацевтический препарат, содержащий производное бензимидазола, смешанное с микрокристаллической целлюлозой, и способ его изготовления
US20040028737A1 (en) * 2002-08-12 2004-02-12 Kopran Research Laboratories Limited Enteric coated stable oral pharmaceutical composition of acid unstable drug and process for preparing the same
WO2004066982A1 (en) * 2003-01-31 2004-08-12 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and processes for their preparation
EP1638607A1 (en) * 2003-04-08 2006-03-29 Progenics Pharmaceuticals, Inc. Combination therapy for constipation comprising a laxative and a peripheral opioid antagonist
MXPA05010819A (es) * 2003-04-08 2006-03-30 Progenics Pharm Inc Uso de antagonistas de opioide perifericos, especialmente metilnaltrexona para tratar sindrome de intestino irritable.
CA2811272C (en) * 2003-04-08 2016-12-20 Progenics Pharmaceuticals, Inc. Pharmaceutical formulations containing methylnaltrexone
ES2234393B2 (es) * 2003-04-29 2006-09-01 Laboratorios Belmac, S.A. "formulaciones de pelets de compuestos bencimidazolicos antiulcerosos y labiles al acido".
WO2004098573A1 (en) * 2003-05-08 2004-11-18 Natco Pharma Limited An improved and stable pharmaceutical composition containing substituted benzimidazoles and a process for its preparation
JPWO2005011637A1 (ja) * 2003-08-04 2006-09-14 エーザイ株式会社 用時分散型製剤
WO2005034924A1 (en) * 2003-10-14 2005-04-21 Natco Pharma Limited Enteric coated pellets comprising esomeprazole, hard gelatin capsule containing them, and method of preparation
GB0400781D0 (en) * 2004-01-14 2004-02-18 Novartis Ag Organic compounds
CA2558535A1 (en) * 2004-03-03 2005-10-06 Teva Pharmaceutical Industries Ltd. A stable pharmaceutical composition comprising an acid labile drug
ES2376466T3 (es) 2004-05-07 2012-03-14 Nycomed Gmbh Forma de dosificación farmacéutica que comprende peletes, as�? como su procedimiento de fabricación.
US20050281876A1 (en) 2004-06-18 2005-12-22 Shun-Por Li Solid dosage form for acid-labile active ingredient
US8658216B2 (en) 2004-12-23 2014-02-25 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
WO2006066932A1 (en) * 2004-12-24 2006-06-29 Lek Pharmaceuticals D.D. Stable pharmaceutical composition comprising an active substance in the form of solid solution
EP1833469A2 (en) * 2005-01-03 2007-09-19 Lupin Ltd. Pharmaceutical composition of acid labile substances
EP1845989A1 (en) * 2005-01-20 2007-10-24 Progenics Pharmaceuticals, Inc. Use of methylnaltrexone and related compounds to treat post-operative gastrointestinal dysfunction
WO2006087613A2 (en) * 2005-02-02 2006-08-24 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions prepared by non-aqueous layering process
ES2714198T3 (es) 2005-03-07 2019-05-27 Univ Chicago Uso de antagonistas opioideos para atenuar la proliferación y la migración de células endoteliales
US9662325B2 (en) 2005-03-07 2017-05-30 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8518962B2 (en) 2005-03-07 2013-08-27 The University Of Chicago Use of opioid antagonists
US8524731B2 (en) * 2005-03-07 2013-09-03 The University Of Chicago Use of opioid antagonists to attenuate endothelial cell proliferation and migration
US8673352B2 (en) * 2005-04-15 2014-03-18 Mcneil-Ppc, Inc. Modified release dosage form
US7803817B2 (en) * 2005-05-11 2010-09-28 Vecta, Ltd. Composition and methods for inhibiting gastric acid secretion
US7981908B2 (en) * 2005-05-11 2011-07-19 Vecta, Ltd. Compositions and methods for inhibiting gastric acid secretion
AR057325A1 (es) 2005-05-25 2007-11-28 Progenics Pharm Inc Sintesis de (s)-n-metilnaltrexona, composiciones farmaceuticas y usos
AR057035A1 (es) 2005-05-25 2007-11-14 Progenics Pharm Inc SíNTESIS DE (R)-N-METILNALTREXONA, COMPOSICIONES FARMACÉUTICAS Y USOS
US20080194611A1 (en) * 2005-06-03 2008-08-14 Alverdy John C Modulation of Cell Barrier Dysfunction
EP1785135A1 (en) 2005-11-10 2007-05-16 Laboratorios Del Dr. Esteve, S.A. New stabilized galenic formulations comprising lansoprazole and their preparation
EP1962844A2 (en) * 2005-12-20 2008-09-03 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
EP1813275A1 (en) * 2005-12-20 2007-08-01 Teva Pharmaceutical Industries Ltd Lansoprazole orally disintegrating tablets
US7579476B2 (en) * 2006-02-24 2009-08-25 Praktikatalyst Pharma, Llc Transition metal mediated oxidation of hetero atoms in organic molecules coordinated to transition metals
ITMI20061024A1 (it) * 2006-05-25 2007-11-26 Eurand Pharmaceuticals Ltd Pellet a base di acido lipoico
PL2046334T3 (pl) * 2006-07-25 2015-02-27 Vecta Ltd Kompozycje i sposoby hamowania wydzielania kwasów żołądkowych z wykorzystaniem pochodnych małych kwasów dikarboksylowych w połączeniu z PPI
TWI489984B (zh) 2006-08-04 2015-07-01 Wyeth Corp 用於非經腸道傳輸化合物之配方及其用途
TW200817048A (en) * 2006-09-08 2008-04-16 Wyeth Corp Dry powder compound formulations and uses thereof
EP2565195B1 (en) * 2007-03-29 2015-05-06 Wyeth LLC Peripheral opioid receptor and antagonists and uses thereof
PL2137191T3 (pl) * 2007-03-29 2016-12-30 Antagoniści obwodowego receptora opioidowego i ich zastosowania
JP2010522756A (ja) * 2007-03-29 2010-07-08 プロジェニックス ファーマシューティカルズ，インコーポレーテッド 結晶形およびその使用
AU2008349873B2 (en) 2008-02-06 2014-02-13 Progenics Pharmaceuticals, Inc. Preparation and use of (R),(R)-2,2'-bis-methylnaltrexone
US8911787B2 (en) 2008-02-26 2014-12-16 Ranbaxy Laboratories Limited Stable oral benzimidazole compositions and process of preparation thereof
CA2719134C (en) 2008-03-21 2015-06-30 The University Of Chicago Treatment with opioid antagonists and mtor inhibitors
CA2729582C (en) 2008-07-01 2017-09-19 University Of Chicago Particles containing an opioid receptor antagonist and methods of use
CH699302B1 (de) * 2008-08-11 2012-03-15 Mepha Gmbh Orale pharmazeutische Formulierung für Omeprazol, enthaltend eine spezifische Trennschicht.
EP2313088A2 (en) * 2008-08-11 2011-04-27 Mepha GmbH Oral pharmaceutical formulation for omeprazole comprising a specific separation layer
CA2676881C (en) 2008-09-30 2017-04-25 Wyeth Peripheral opioid receptor antagonists and uses thereof
WO2010117756A2 (en) * 2009-03-31 2010-10-14 Dr. Reddy's Laboratories Ltd Substituted benzimidazole pharmaceutical formulations
US20130202688A1 (en) 2010-05-04 2013-08-08 Sunilendu Bhushan Roy Delayed release oral disintegrating pharmaceutical compositions of lansoprazole
HK1201477A1 (en) * 2011-11-02 2015-09-04 Laboratorios Del. Dr. Esteve, S.A. Pharmaceutical composition of omeprazole
GB2513172A (en) * 2013-04-18 2014-10-22 Nupharm Lab Ltd Liquid dosage form and delivery system
JP6686013B2 (ja) 2014-10-17 2020-04-22 サリックス ファーマスーティカルズ，インコーポレーテッド 腫瘍の進行を減弱させるためのメチルナルトレキソンの使用
US20170042806A1 (en) 2015-04-29 2017-02-16 Dexcel Pharma Technologies Ltd. Orally disintegrating compositions
US10076494B2 (en) 2016-06-16 2018-09-18 Dexcel Pharma Technologies Ltd. Stable orally disintegrating pharmaceutical compositions

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519365A1 (de) * 1991-06-17 1992-12-23 Byk Gulden Lomberg Chemische Fabrik GmbH Pantoprazol enthaltende orale Darreichungsformen
EP0519144A1 (en) * 1991-06-21 1992-12-23 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets

Family Cites Families (22)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB829055A (en) * 1958-02-07 1960-02-24 Charles E Frosst And Company Improvements in or relating to pharmaceutical preparations
US4150111A (en) * 1974-05-28 1979-04-17 Allister Warren Enteric coated magnesium chloride
JPS5837285B2 (ja) * 1975-05-29 1983-08-15 カブシキガイシヤ ミドリジユウジ チヨウナイカンセンシヨウチリヨウザイノセイゾウホウホウ
JPS5598120A (en) * 1979-01-16 1980-07-25 Shin Etsu Chem Co Ltd Preparation of drug having enteric coating
US4470980A (en) * 1980-03-07 1984-09-11 Interx Research Corp. Method of increasing oral absorption of β-lactam antibiotics
US4377568A (en) * 1981-08-12 1983-03-22 Merck Sharp & Dohme (I.A.) Corp. Preparation of aqueous alcoholic dispersions of pH sensitive polymers and plasticizing agents and a method of enteric coating dosage forms using same
JPS58208155A (ja) * 1982-05-28 1983-12-03 Sumitomo Electric Ind Ltd 光伝送用ガラスフアイバの製造方法
JPS59193831A (ja) * 1983-04-18 1984-11-02 Sankyo Co Ltd 腸溶性製剤の製造法
CA1327010C (en) * 1986-02-13 1994-02-15 Tadashi Makino Stabilized solid pharmaceutical composition containing antiulcer benzimidazole compound and its production
GB2189698A (en) 1986-04-30 1987-11-04 Haessle Ab Coated omeprazole tablets
US5026560A (en) * 1987-01-29 1991-06-25 Takeda Chemical Industries, Ltd. Spherical granules having core and their production
JPH0768125B2 (ja) * 1988-05-18 1995-07-26 エーザイ株式会社 酸不安定化合物の内服用製剤
IT1230576B (it) * 1988-10-20 1991-10-28 Angeli Inst Spa Formulazioni farmaceutiche per via orale a liberazione selettiva nel colon
US5395611A (en) * 1990-04-24 1995-03-07 The Governors Of The University Of Alberta Phenolic amine depigmenting and antimelanoma agents
IT1241740B (it) * 1990-06-22 1994-02-01 Edi Bondioli Protezione per una forcella di estremita' di un albero cardanico
JP2773959B2 (ja) * 1990-07-10 1998-07-09 信越化学工業株式会社 大腸内放出性固形製剤
US5316772A (en) * 1990-12-19 1994-05-31 Solvay & Cie, S.A. (Societe Anonyme) Bilayered oral pharmaceutical composition with pH dependent release
US5232706A (en) * 1990-12-31 1993-08-03 Esteve Quimica, S.A. Oral pharmaceutical preparation containing omeprazol
FR2692146B1 (fr) 1992-06-16 1995-06-02 Ethypharm Sa Compositions stables de microgranules d'omeprazole gastro-protégés et leur procédé d'obtention.
AU4513393A (en) * 1992-07-17 1994-02-14 Astra Aktiebolag Pharmaceutical composition containing antiulcer agent
SE9402431D0 (sv) * 1994-07-08 1994-07-08 Astra Ab New tablet formulation
SE9500478D0 (sv) 1995-02-09 1995-02-09 Astra Ab New pharmaceutical formulation and process

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP0519365A1 (de) * 1991-06-17 1992-12-23 Byk Gulden Lomberg Chemische Fabrik GmbH Pantoprazol enthaltende orale Darreichungsformen
EP0519144A1 (en) * 1991-06-21 1992-12-23 Ilsan Ilac Ve Hammaddeleri Sanayi A.S. New galenic process for omeprazole containing pellets

Cited By (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6576258B1 (en) 1997-07-14 2003-06-10 Lek, Tovarna Farmacevtskih In Kemicnih Izdelkov, D.D. Pharmaceutical formulation with controlled release of active substances
US6391342B1 (en) 1998-03-20 2002-05-21 A/S Gea Farmaceutisk Fabrik Pharmaceutical formulation comprising a 2- [(2-pyridinyl) methyl] sulfinyl benzimidazole having anti-ulcer activity and a process for the preparation of such formulation
WO1999053918A1 (en) 1998-04-20 1999-10-28 Eisai Co., Ltd. Stabilized compositions containing benzimidazole-type compounds
US7402321B2 (en) 1998-08-12 2008-07-22 Nycomed Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H-benzimidazoles
US8465767B2 (en) 1998-08-12 2013-06-18 Takeda Gmbh Oral administration form for pyridin-2-ylmethylsulfinyl-1H benzimidazoles
US7544370B2 (en) 2003-10-01 2009-06-09 Wyeth Pantoprazole multiparticulate formulations
US7550153B2 (en) 2003-10-01 2009-06-23 Wyeth Pantoprazole multiparticulate formulations
US7553498B2 (en) 2003-10-01 2009-06-30 Wyeth Pantoprazole multiparticulate formulations
US7838027B2 (en) 2003-10-01 2010-11-23 Wyeth Llc Pantoprazole multiparticulate formulations
EP3292862A1 (en) 2016-09-07 2018-03-14 Sandoz Ag Omeprazole formulations
WO2018046498A1 (en) 2016-09-07 2018-03-15 Sandoz Ag Omeprazole formulations

Also Published As

Publication number Publication date
DE69634613T2 (de) 2006-03-09
CA2184842A1 (en) 1996-08-08
ATE292967T1 (de) 2005-04-15
KR100331290B1 (ko) 2002-11-22
EP0993830A3 (en) 2001-10-04
JP4183746B2 (ja) 2008-11-19
IL116673A0 (en) 1996-05-14
HUP9603014A2 (hu) 1998-03-30
IL116673A (en) 2000-10-31
SI0773025T1 (en) 2000-10-31
HUP9603014A3 (en) 2000-12-28
EP0993830B1 (en) 2005-04-13
TW503115B (en) 2002-09-21
ES2094694A1 (es) 1997-01-16
DE69634613D1 (de) 2005-05-19
EP0993830A2 (en) 2000-04-19
FI121730B (fi) 2011-03-31
HU229219B1 (en) 2013-09-30
PT993830E (pt) 2005-06-30
SI0993830T1 (en) 2005-10-31
AU4540396A (en) 1996-08-21
DE69608767D1 (de) 2000-07-13
DK0993830T3 (da) 2005-08-08
EP0773025A1 (en) 1997-05-14
ATE193649T1 (de) 2000-06-15
FI963916L (fi) 1996-09-30
ES2094694B1 (es) 1997-12-16
DK0773025T3 (da) 2000-10-09
IN186596B (https=) 2001-10-06
EP0773025B1 (en) 2000-06-07
AR002702A1 (es) 1998-04-29
DE29623938U1 (de) 2000-10-05
ES2238796T3 (es) 2005-09-01
ES2148725T3 (es) 2000-10-16
CA2184842C (en) 2007-08-07
FI963916A0 (fi) 1996-09-30
ZA96683B (en) 1997-09-23
US5626875A (en) 1997-05-06
JPH09511257A (ja) 1997-11-11
PT773025E (pt) 2000-10-31

Similar Documents

Publication Publication Date Title
WO1996023500A1 (es) Nuevas formulaciones galenicas estables conteniendo un compuesto de bencimidazol acido-labil, y su proceso de obtencion
ES2218054T3 (es) Nueva composicion que contiene lansoprazol, y procedimiento para su preparacion.
US4786505A (en) Pharmaceutical preparation for oral use
ES2286119T3 (es) Composicion de recubrimiento para enmascarar el sabor.
ES2977953T3 (es) Comprimido
EP2098250A1 (en) Orally disintegrating solid preparation
ES2667402T3 (es) Composición farmacéutica de omeprazol
ES2336757B1 (es) Nuevas formulaciones galenicas estabilizadas que comprenden lansoprazol y su preparacion.
JPH0873345A (ja) 医薬製剤
EP2558079B1 (en) Ciprofloxacin dry syrup composition
KR100523082B1 (ko) 쓴 맛이 은폐된 세푸록심악세틸 제제의 제약조성물 및 그의 제조방법

Legal Events

Date Code Title Description
AK Designated states

Kind code of ref document: A1

Designated state(s): AL AM AT AT AU AZ BB BG BR BY CA CH CN CZ CZ DE DE DK DK EE EE FI FI GB GE HU IS JP KE KG KP KR KZ LK LR LS LT LU LV MD MG MK MN MW MX NO NZ PL PT RO RU SD SE SG SI SK SK TJ TM TR TT UA UG UZ VN AZ BY KG KZ RU TJ TM

AL Designated countries for regional patents

Kind code of ref document: A1

Designated state(s): KE LS MW SD SZ UG AT BE CH DE DK ES FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM

WWE Wipo information: entry into national phase

Ref document number: 2184842

Country of ref document: CA

WWE Wipo information: entry into national phase

Ref document number: 1996901349

Country of ref document: EP

121 Ep: the epo has been informed by wipo that ep was designated in this application
REG Reference to national code

Ref country code: DE

Ref legal event code: 8642

WWP Wipo information: published in national office

Ref document number: 1996901349

Country of ref document: EP

WWG Wipo information: grant in national office

Ref document number: 1996901349

Country of ref document: EP

WWW Wipo information: withdrawn in national office

Ref document number: 1996901349

Country of ref document: EP